Skip to Content
Merck
CN
  • Prenatal vitamin K1 administration in epileptic women to prevent neonatal hemorrhage: is it effective?

Prenatal vitamin K1 administration in epileptic women to prevent neonatal hemorrhage: is it effective?

The Journal of reproductive medicine (2006-07-19)
Waralak Yamasmit, Surasith Chaithongwongwatthana, Jorge E Tolosa
ABSTRACT

To summarize current knowledge on whether prenatal prophylactic vitamin K1 administration to epileptic women receiving enzyme-inducing antiepileptic drugs (AEDs) to prevent neonatal hemorrhage is effective. A computerized MEDLINE search was conducted using the terms antiepileptic drug, hemorrhagic disease of the newborn, pregnancy and vitamin K since 1966 to July 2004, limited only to human studies. English-language publications were selected based on their relevance to the clinical effectiveness of administration of oral vitamin K to epileptic women exposed to enzyme-inducing AEDs for prevention of hemorrhagic disease of the newborn (HDN). No randomized, controlled trial testing prenatal vitamin K1 administration for reducing the incidence or severity of neonatal hemorrhage was identified. This review summarizes the data from published observational studies. There is inadequate evidence to recommend the routine administration of prenatal vitamin K to epileptic women exposed to enzyme-inducing AED therapy in order to prevent HDN.

MATERIALS
Product Number
Brand
Product Description

Supelco
Phylloquinone (K1), analytical standard
Sigma-Aldrich
Vitamin K1, viscous liquid
Phytomenadione, European Pharmacopoeia (EP) Reference Standard
Supelco
Phytonadione, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Vitamin K1, BioXtra, ≥99.0% (sum of isomers, HPLC), mixture of isomers